about
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.Current treatments for renal failure due to multiple myeloma.Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.Differences between warfarin and new oral anticoagulants in dental clinical practice.Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.The future of anticoagulant therapy.The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
P2860
Q33398044-B6F7A4A2-7280-4F1D-B9AF-4151A023AF17Q33398587-39BFA440-7D18-4075-92E9-D129D3D3F178Q33421008-CCDFF6F4-CE18-4C63-B6B0-E76E7FA751CEQ33831680-BA33E0A3-E61E-48F4-8047-87B96CD228E2Q35244883-A9171CF5-3710-42B3-8077-079A56079B5FQ36301287-C9B51C1D-0A79-43E5-A853-D8A9433D69F8Q37835695-6E4DAEB0-C7AD-4593-8592-D5BAB5E193F6Q37949201-819D1BC5-9858-49D4-AA6D-72F0EE00D571Q37978343-3FB169D1-9CFB-4D20-B304-A25A117B4023Q37986358-A6F1425B-B997-443F-81FC-725C131D481EQ38096085-6E262804-5A39-4B92-8F7F-4B9C36B4FA3AQ38109235-D62751D1-8E45-414D-A7AF-4EF533948772Q38856521-CC1539E6-2F45-4371-9D04-7793CAB8AF64Q39064465-08E579CE-19B1-4524-86C0-2FF0D7E5722BQ42925566-AEEC54CF-50AB-43AD-846C-F5221DC276A3Q51682044-06C95F3B-1E44-4140-AFF1-E5BB7EF20DA8Q57904432-A03AB919-0ADA-41E0-BBFD-7594AAC7DE22
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Meeting the unmet needs in anticoagulant therapy.
@en
Meeting the unmet needs in anticoagulant therapy.
@nl
type
label
Meeting the unmet needs in anticoagulant therapy.
@en
Meeting the unmet needs in anticoagulant therapy.
@nl
prefLabel
Meeting the unmet needs in anticoagulant therapy.
@en
Meeting the unmet needs in anticoagulant therapy.
@nl
P2860
P1476
Meeting the unmet needs in anticoagulant therapy.
@en
P2093
Jeffrey I Weitz
P2860
P356
10.1111/J.1600-0609.2010.01461.X
P577
2010-07-01T00:00:00Z